Status:

RECRUITING

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Lead Sponsor:

Johnson & Johnson Enterprise Innovation Inc.

Conditions:

Carcinoma, Non-small-Cell Lung

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Eligibility Criteria

Inclusion

  • Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
  • Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\], c-ros oncogene 1 \[ROS1\], v-raf murine sarcoma viral oncogene homolog B1 \[BRAF\]) must have received all approved targeted therapies and have progressed
  • Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1\], and BRAF \[B-Raf proto-oncogene, serine/threonine kinase\])
  • Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy
  • For Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for metastatic disease as the prior line of therapy
  • For Cohort C of Part 2: Treatment naïve
  • Adequate organ function

Exclusion

  • Active central nervous system (CNS) disease involvement
  • Active autoimmune disease
  • Active infection
  • History of solid organ or hematologic stem cell transplantation

Key Trial Info

Start Date :

November 27 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 7 2029

Estimated Enrollment :

126 Patients enrolled

Trial Details

Trial ID

NCT06116786

Start Date

November 27 2023

End Date

June 7 2029

Last Update

December 5 2025

Active Locations (15)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (15 locations)

1

City of Hope

Newnan, Georgia, United States, 30265

2

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

3

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States, 14203

4

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

New York, New York, United States, 10032